3',5'-di-O-acetyl-5-(1-fluoro-2-bromoethyl)-2'-deoxyuridine | 871918-18-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 3',5'-di-O-acetyl-5-(1-fluoro-2-bromoethyl)-2'-deoxyuridine
• 英文别名: 5-(1-fluoro-2-bromoethyl)-3',5'-di-O-acetyl-2'-deoxyuridine；[(2R,3S,5R)-3-acetoxy-5-[5-(2-bromo-1-fluoro-ethyl)-2,4-dioxo-pyrimidin-1-yl]tetrahydrofuran-2-yl]methyl acetate；[(2R,3S,5R)-3-acetyloxy-5-[5-(2-bromo-1-fluoroethyl)-2,4-dioxopyrimidin-1-yl]oxolan-2-yl]methyl acetate
• CAS: 871918-18-2
• 化学式: C₁₅H₁₈BrFN₂O₇
• 分子量: 437.22
• InChiKey: LJMDNOKWOOPRIO-FJAVPRTDSA-N

物化性质

• 密度：
  1.60±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3',5'-di-O-acetyl-5-(1-fluoro-2-bromoethyl)-2'-deoxyuridine 在 氨 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以50%的产率得到3-[2-deoxy-β-D-ribofuranosyl]-furo[2,3-d]pyrimidin-2(3H)-one
  参考文献：
  名称：

  5-（1,2-二卤乙基）-2'-脱氧尿苷及相关类似物的合成及性质

  摘要：

  AbstractThe regiospecific reaction of 5‐vinyl‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (2) with HOX (X = Cl, Br, I) yielded the corresponding 5‐(1‐hydroxy‐2‐haloethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridines 3a‐c. Alternatively, reaction of 2 with iodine monochloride in aqueous acetonitrile also afforded 5‐(1‐hydroxy‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3c). Treatment of 5‐(1‐hydroxy‐2‐chloroethyl)‐ (3a) and 5‐(1‐hydroxy‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3b) with DAST (Et2NSF3) in methylene chloride at ‐40° gave the respective 5‐(1‐fluoro‐2‐chloroethyl)‐ (6a, 74%) and 5‐(1‐fluoro‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6b, 65%). In contrast, 5‐(1‐fluoro‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6e) could not be isolated due to its facile reaction with methanol, ethanol or water to yield the corresponding 5‐(1‐methoxy‐2‐iodoethyl)‐ (6c), 5‐(1‐ethoxy‐2‐iodoethyl)‐ (6d) and 5‐(1‐hydroxy‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3c). Treatment of 5‐(1‐hydroxy‐2‐chloroethyl)‐ (3a) and 5‐(1‐hydroxy‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3b) with thionyl chloride yielded the respective 5‐(1,2‐dichloroethyl)‐ (6f, 85%) and 5‐(1‐chloro‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6g, 50%), whereas a similar reaction employing the 5‐(1‐hydroxy‐2‐iodoethyl)‐ compound 3c afforded 5‐(1‐methoxy‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6c), possibly via the unstable 5‐(1‐chloro‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine intermediate 6h. The 5‐(1‐bromo‐2‐chloroethyl)‐ (6i) and 5‐(1,2‐dibromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6j) could not be isolated due to their facile conversion to the corresponding 5‐(1‐ethoxy‐2‐chloroethyl)‐ (6k) and 5‐(1‐ethoxy‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (61). Reaction of 5‐(1‐hydroxy‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3b) with methanolic ammonia, to remove the 3′,5′‐di‐O‐acetyl groups, gave 2,3‐dihydro‐3‐hydroxy‐5‐(2′‐deoxy‐β‐D‐ribofuranosyl)‐furano[2,3‐d]pyrimidine‐6(5H)‐one (8). In contrast, a similar reaction of 5‐(1‐fluoro‐2‐chloroethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6a) yielded (E)‐5‐(2‐chlorovinyl)‐2′‐deoxyuridine (1b, 23%) and 5‐(2′‐deoxy‐β‐D‐ribofuranosyl)furano[2,3‐d]pyrimidin‐6(5H)‐one (9, 13%). The mechanisms of the substitution and elimination reactions observed for these 5‐(1,2‐dihaloethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridines are described.

  DOI：

  10.1002/jhet.5570280819
• 作为产物：
  描述：

  5-(1-hydroxy-2-bromoethyl)-3',5'-di-O-acetyl-2'-deoxyuridine 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以65%的产率得到3',5'-di-O-acetyl-5-(1-fluoro-2-bromoethyl)-2'-deoxyuridine
  参考文献：
  名称：

  5-（1,2-二卤乙基）-2'-脱氧尿苷及相关类似物的合成及性质

  摘要：

  AbstractThe regiospecific reaction of 5‐vinyl‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (2) with HOX (X = Cl, Br, I) yielded the corresponding 5‐(1‐hydroxy‐2‐haloethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridines 3a‐c. Alternatively, reaction of 2 with iodine monochloride in aqueous acetonitrile also afforded 5‐(1‐hydroxy‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3c). Treatment of 5‐(1‐hydroxy‐2‐chloroethyl)‐ (3a) and 5‐(1‐hydroxy‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3b) with DAST (Et2NSF3) in methylene chloride at ‐40° gave the respective 5‐(1‐fluoro‐2‐chloroethyl)‐ (6a, 74%) and 5‐(1‐fluoro‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6b, 65%). In contrast, 5‐(1‐fluoro‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6e) could not be isolated due to its facile reaction with methanol, ethanol or water to yield the corresponding 5‐(1‐methoxy‐2‐iodoethyl)‐ (6c), 5‐(1‐ethoxy‐2‐iodoethyl)‐ (6d) and 5‐(1‐hydroxy‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3c). Treatment of 5‐(1‐hydroxy‐2‐chloroethyl)‐ (3a) and 5‐(1‐hydroxy‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3b) with thionyl chloride yielded the respective 5‐(1,2‐dichloroethyl)‐ (6f, 85%) and 5‐(1‐chloro‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6g, 50%), whereas a similar reaction employing the 5‐(1‐hydroxy‐2‐iodoethyl)‐ compound 3c afforded 5‐(1‐methoxy‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6c), possibly via the unstable 5‐(1‐chloro‐2‐iodoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine intermediate 6h. The 5‐(1‐bromo‐2‐chloroethyl)‐ (6i) and 5‐(1,2‐dibromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6j) could not be isolated due to their facile conversion to the corresponding 5‐(1‐ethoxy‐2‐chloroethyl)‐ (6k) and 5‐(1‐ethoxy‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (61). Reaction of 5‐(1‐hydroxy‐2‐bromoethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (3b) with methanolic ammonia, to remove the 3′,5′‐di‐O‐acetyl groups, gave 2,3‐dihydro‐3‐hydroxy‐5‐(2′‐deoxy‐β‐D‐ribofuranosyl)‐furano[2,3‐d]pyrimidine‐6(5H)‐one (8). In contrast, a similar reaction of 5‐(1‐fluoro‐2‐chloroethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridine (6a) yielded (E)‐5‐(2‐chlorovinyl)‐2′‐deoxyuridine (1b, 23%) and 5‐(2′‐deoxy‐β‐D‐ribofuranosyl)furano[2,3‐d]pyrimidin‐6(5H)‐one (9, 13%). The mechanisms of the substitution and elimination reactions observed for these 5‐(1,2‐dihaloethyl)‐3′,5′‐di‐O‐acetyl‐2′‐deoxyuridines are described.

  DOI：

  10.1002/jhet.5570280819

文献信息

• ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES
  申请人：University College Cardiff Consultants Limited

  公开号：EP0980377B1

  公开（公告）日：2002-07-31
• US6573247B1
  申请人：——

  公开号：US6573247B1

  公开（公告）日：2003-06-03
• US7019135B2
  申请人：——

  公开号：US7019135B2

  公开（公告）日：2006-03-28
• [EN] ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES<br/>[FR] ANALOGUES DE NUCLEOSIDE PYRIMIDIQUE A ACTION ANTIVIRALE
  申请人：UNIV CARDIFF

  公开号：WO2001085749A1

  公开（公告）日：2001-11-15

  A compound, which can show potent anti-viral activity against, for example, cytomegalo virus, has the formula (I), wherein R is selected from the group comprising, optionally substituted, C5 to C20 alkyl and, optionally substituted, C5 to C20 cycloalkyl; R' is selected from the group comprising hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyoxy, aryloxy, thiol, alkylthiol, arythiol, alkyl; R' is selected from the group comprising hydrogen, alkyl, cycloalkyl, halogens, alkyloxy, aryloxy and aryl; Q is selected from the group comprising O, NH, S, N-alkyl and CY2, where Y may be the same or different and is selected from H, alkyl and halogens; X is selected from the group comprising O, NH, S, Se, N-alkyl, (CH2)n where n is 1 to 10, and CY2 where Y may be the same or different and is selected from hydrogen, alkyl and halogens; Z is selected from the group comprising O, S, NH, and N-alkyl; T is selected from the group comprising H, halogens, alkyl (C1 to C10), O-alkyl (C1 to C10), N3 and CN; T' is selected from the group comprising H, halogens, O-alkyl (C1 to C10), N3 and CN; or T and T' together form a bridge which is selected from the group comprising -O-, -NH- and -(CH2)p- wherein p is an integer from 1 to 6; T' is selected from the group comprising H, OH, halogens, N3 and CN; T''' is selected from the group comprising H, OH, halogens, N3 and CN; or T' and T''' together form a bridge which is selected from the group comprising -O-, -NH- and -(CH2)p- wherein p is an integer from 1 to 6; or T and T''' together form =CH2; and W is selected from the group comprising H, a phosphate group a phosphonate group; and a pharmacologically acceptable salt, derivative or pro-drug thereof.